| Trial ID: | L2735 |
| Source ID: | NCT01204580
|
| Associated Drug: |
Glimepiride + Metformin
|
| Title: |
ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination
|
| Acronym: |
DIAGRAM
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GLIMEPIRIDE + METFORMIN
|
| Outcome Measures: |
Primary: Adiponectin and Asymmetric Dimethylarginine (ADMA) plasma level changes, from baseline to end of Clinical Trial (12 weeks) | Secondary: Change in adiponectin and Asymmetric Dimethylarginine (ADMA) plasma levels, at week 8|Pulse Wave Velocity (PWV) change, at week 8 and week 12|Change in Fasting Blood Glucose (FBG), At week 2, 4, 8 and 12|Change in glycosylated hemoglobin (HbA1c), at week 12|Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment (HOMA-β), At week 12|Change of Tumor Necrosis Factor- Alfa (TNF-Alfa), At week 12
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
40
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2010-12
|
| Completion Date: |
2012-03
|
| Results First Posted: |
|
| Last Update Posted: |
2012-04-03
|
| Locations: |
Sanofi-Aventis Administrative Office, Jakarta, Indonesia
|
| URL: |
https://clinicaltrials.gov/show/NCT01204580
|
